Literature DB >> 18266008

Exemestane: the dawn of a new era in breast cancer treatment.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18266008     DOI： 10.1007/s00432-008-0363-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  7 in total

Review 1.  Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials.

Authors:  Carsten Rose
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-16       Impact factor: 4.553

2.  The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

Authors:  C Markopoulos; A Polychronis; V Zobolas; G Xepapadakis; J Papadiamantis; D Koukouras; H Lappas; H Gogas
Journal:  Breast Cancer Res Treat       Date:  2005-09       Impact factor: 4.872

3.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Authors:  Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

4.  Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

Authors:  T A Traina; I Poggesi; M Robson; A Asnis; B A Duncan; A Heerdt; C Dang; D Lake; M Moasser; K Panageas; P Borgen; L Norton; C Hudis; M N Dickler
Journal:  Breast Cancer Res Treat       Date:  2007-10-20       Impact factor: 4.872

5.  Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.

Authors:  Nancy A Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

6.  Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.

Authors:  David Thompson; Douglas C A Taylor; Eduardo L Montoya; Eric P Winer; Stephen E Jones; Milton C Weinstein
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

7.  Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

Authors:  Stephen E Jones; James Cantrell; Svetislava Vukelja; John Pippen; Joyce O'Shaughnessy; Joanne L Blum; Robert Brooks; Nicole L Hartung; Angel G Negron; Donald A Richards; Ragene Rivera; Frankie Ann Holmes; Sreeni Chittoor; Thomas L Whittaker; James H Bordelon; Steven J Ketchel; Jennifer C Davis; Des Ilegbodu; Jean Kochis; Lina Asmar
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.